Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Prudential Financial Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Prudential Financial Inc trades at $122.04 (market cap $42.20B). The key difference: Prudential Financial Inc is far larger — about 8.3× ACADIA Pharmaceuticals Inc.'s market cap, and Prudential Financial Inc pays a 4.58% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PRU | |
|---|---|---|
Market Cap | $5.07B | $42.20B |
Sector | Health | Financials |
52-Week High | $29.41 | $123.93 |
52-Week Low | $20.06 | $92.00 |
Enterprise Value | $4.19B | $70.98B |
Dividend Yield | — | 4.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Prudential Financial (PRU) trades at $122.11, up 0.68% today, with a bullish technical signal and strong Q2 2026 earnings beats. The stock shows solid fundamentals with a P/E of 11.09, ROE of 12.46%, and a $1.40 quarterly dividend. Recent news highlights strategic growth in wealth management and PGIM strength, though China tax concerns caused volatility.
Outlook is cautiously positive given earnings momentum and capital-light strategy, but risks include regulatory uncertainty in China and mixed analyst sentiment with 67.57% hold ratings. The consensus price target of $113.11 suggests limited upside from current levels, requiring monitoring of international operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
